Deposition of immune complexes (ICs) is a major initiation step for many types of glomerulonephritis. After deposition in tissues, the Fc portion of immunoglobulins (Ig) in ICs binds to Fc receptors (FcRs) on effector cells. In the mouse, four Fc␥Rs for IgG have been identified. 1, 2 Among them, Fc␥RI, III, and IV are polymeric receptors with a common ␥ adaptor chain (FcR␥) bearing the immunoreceptor tyrosine-based activation motif. The FcR␥ chain is necessary for cell surface expression and signal transduction of Fc␥RI, III, and IV. The FcR␥ chain is also a subunit of FcRI and Fc␣RI. 3, 4 Binding of Fc␥RI, III, and IV by IgG transduces activating signals via phosphorylation of the FcR␥ immunoreceptor tyrosine-based activation motif leading to activation of syk tyrosine kinase and downstream signaling pathways such as phospholipase C-␥ and phosphatidylinositol-3 kinase. Deletion of the FcR␥ subunit leads to functional loss of Fc␥RI, III, and IV. 5 In contrast, the monomeric Fc␥RIIb has an immunoreceptor tyrosine-based inhibitory motif in its cytoplasmic tail. Ligand binding to Fc␥RIIb leads to recruitment of inhibitory phosphatases such as src homology domain type-2-containing tyrosine phosphatase 1 and SH2-containing inositol polyphosphate phosphatase that dampen immunoreceptor tyrosine-based activation motif-initiated activation. 1, 6 An emerging paradigm for the mediation of inflammation is that a balancing of engagement of coexisting activating and inhibitory Fc␥Rs on the surface of effector cells determines the severity of inflammatory response to injury. 4, 7 Membranoproliferative glomerulonephritis (MPGN) in humans is typically initiated by deposition of immune complexes. The mechanism by which MPGN develops subsequent to immune complex deposition is still not well understood. We have characterized a mouse model of MPGN resulting from deposition of cryoglobulin containing ICs, which result from overexpression of thymic stromal lymphopoietin (TSLP), a cytokine that causes abnormalities in B cell development. 8, 9 TSLP transgenic (TSLPtg) mice develop mixed cryoglobulinemia and a systemic inflammatory disease that involves the kidney, lung, spleen, liver, and skin. These mice develop renal disease that closely resembles human cryoglobulinemia-associated MPGN. 8 The glomerular injury in these mice is characterized by extensive subendothelial and mesangial immune deposits, marked macrophage influx, and mesangial cell proliferation and matrix expansion. Immunofluorescence microscopy shows massive glomerular deposition of immunoglobulins and complement.
We have studied the effect of the inhibitory Fc␥RIIb on this MPGN model previously and showed that Fc␥RIIb deficiency in TSLPtg mice resulted in more severe kidney disease with more infiltrating macrophages and increased cell proliferation in glomeruli. 10 Here we present complementary studies in which the effect of deletion of the activating Fc␥Rs on the disease in this model was tested, and present the surprising result that this intervention produced no improvement in renal and systemic disease in TSLPtg mice and indeed lead to higher concentration of circulating cryoglobulins and more deposition of ICs in the kidney in these mice.
Materials and Methods

Animals
The experimental protocol of this study was reviewed and approved by the Animal Care Committee of the University of Washington. Mice were housed under standard conditions and received normal chow and water ad libitum in a specific pathogen free facility. TSLPtg mice on C57BL/6 background have been reported previously. 8 FcR␥ chain knockout (FcR␥ Ϫ/Ϫ ) mice on C57BL/6 background were provided by J. V. Ravetch (Rockefeller University, New York, NY) and have been described previously.
11 TSLPtg mice were crossed to FcR␥ Ϫ/Ϫ mice. Cohorts of FcR␥ ϩ/ϩ (wild-type), FcR␥ Ϫ/Ϫ , TSLPtg, and TSLPtg/FcR␥ Ϫ/Ϫ mice (n ϭ 6 in each group), all females, were sacrificed and analyzed at age 30 days and 50 days when kidney disease is early in its evolution (30 days) and when it is fully developed (50 days) in female TSLPtg mice, as previously documented. 8, 10 Immune Thrombocytopenia Induced by 6A6 Antibody
To establish the intact function of activating Fc␥Rs in TSLPtg mice, and its absence in TSLPtg/FcR␥ Ϫ/Ϫ mice, a platelet depletion assay that requires the presence of intact Fc␥Rs was used, as previously described. 12, 13 Blood samples were collected from TSLPtg and TSLPtg/ FcR␥ Ϫ/Ϫ mice and placed into EDTA tubes to prevent clotting. The assay utilizes the monoclonal anti-platelet antibody 6A6 (IgG1). 14 Five g 6A6 antibody in 200 l of saline was injected into the tail vein of each mouse. After 4 hours, a second blood sample was collected and placed into an EDTA tube. The blood samples underwent manual count of platelets (Phoenix Central Laboratory, Everett, WA).
Tissue Collection and Histological Staining
Mice were anesthetized and blood was collected before sacrifice by retro-orbital bleeding. Kidney, spleen, liver, and lung were collected at sacrifice. Portions of each organ were fixed in 10% neutral-buffered formalin and methyl Carnoy's solution (60% methanol, 30% chloroform, and 10% acetic acid). These tissues were processed and embedded in paraffin. Four m sections were cut and used in H&E, periodic acid-Schiff, Masson's trichrome, and immunohistochemistry staining. Paraffinembedded kidney tissue was also cut at 2 m and stained with silver methenamine reagents (silver staining). Portions of kidney in OCT were snap-frozen and sectioned at 5 m, fixed in ice-cold acetone for 10 minutes, and then used for immunofluorescence and immunohistochemistry studies.
Analysis of Kidney Function
Before sacrifice, mouse spot urine was collected. Urine albumin was measured by enzyme-linked immunosorbent assay (ELISA) using the Albuwell kit (Exocell, Philadephia, PA) and urine creatinine was measured using the Creatinine Companion kit (Exocell) according to protocols of the manufacturer. Proteinuria was evaluated by urine albumin/creatinine ratio.
Measurements of Serum Cryoglobulins, Immunoglobulins, and TSLP
Blood was allowed to clot at 37°C and serum was collected by centrifugation at 3000 rpm for 10 minutes. Serum was stored at 4°C for a minimum of 72 hours and the formation of cryoprecipitate was identified and serum cryoglobulin concentration (cryocrit) was measured as previous described. 8 
Immunofluorescence
Acetone-fixed frozen kidney sections were air-dried and washed in PBS. Sections were then incubated with fluorescein-conjugated antibodies against mouse IgG, IgM, IgA, and complement C3 (all from Cappel Pharmaceuticals, Aurora, OH). After washing, slides were mounted in Vectashield mounting media (Vector, Burlingame, CA), coverslipped, and viewed under a Zeiss fluorescence microscope. In a blinded manner, the glomerular fluorescence intensity was described semiquantitatively (0, negative; 1, weak; 2, moderate; 3, strong). For every sample, 15 glomeruli were evaluated and mean score was calculated.
Kidney Immunohistochemistry
The general immunohistochemistry protocol used has been described previously. 8, 16 Type IV collagen was de- tected by a goat polyclonal anti-human type IV collagen antibody that cross-reacts with mouse type IV collagen (Southern Biotechnology, Birmingham, AL). Glomerular mesangial cell activation was evaluated by ␣-smooth muscle actin (␣-SMA) expression. Tissues were first blocked by Rodent Block M, (Biocare Medical, Concord, CA). After incubation with a mouse monoclonal anti-human ␣-SMA antibody (Dako, Carpinteria, CA), MM-HRP Polymer (Biocare Medical) was added and then detected with diaminobenzidine substrate. Macrophages were detected using a rat anti-mouse Mac-2 antibody (Cedarlane, Ontario, Canada) in paraffin-embedded tissue or a rat anti-mouse CD68 antibody (Serotech, Raleigh, NC) for frozen tissue. T cells were detected using a rat antimouse CD3 antibody (Dako). Fc␥RI and Fc␥RIII expression in glomeruli was detected using goat anti-mouse Fc␥RI antibody (R&D Systems, Minneapolis, MN) in frozen tissues and goat anti-mouse Fc␥RIII antibody (R&D Systems) in paraffin-embedded tissue, respectively. Double immunolabeling was used to identify the cell types expressing Fc␥RI and Fc␥RIII receptors. For Fc␥RI receptor, frozen kidney tissues were stained with rat antimouse CD68 antibody, followed by detection with Alexa Fluor 488-labeled (green color fluorescence) rabbit antirat secondary antibody (Invitrogen, Carlsbad, California). Tissues were then incubated with goat anti-mouse Fc␥RI antibody followed by Alexa Fluor 593-labeled (red color fluorescence) donkey anti-goat secondary antibody (Invitrogen). For Fc␥RIII receptor, methyl Carnoy's solutionfixed and paraffin-embedded kidney tissues were first stained with rat anti-mouse Mac-2 antibody followed by biotinylated secondary antibody. Positive staining was visualized by Vector VIP substrate kit (purple-blue color in positive areas). Tissues were than incubated with goat anti-mouse Fc␥RIII antibody. Biotinylated anti-goat secondary antibody was added and then visualized by diaminobenzidine substrate (brown color in positive area). Tissues were then counterstained with methyl green. 
Analytical Methods and Statistical Analysis
Fifteen random glomerular cross sections were photographed using an Olympus DP11 digital camera (Olympus, Melville, NY). The photography and subsequent morphological analyses were performed by an examiner blinded to the origin of the samples. The photographs were imported and analyzed using the ImagePro Plus software (Media Cybernetics, Silver Spring, MD). Glomerular tuft area and the proportion of the glomerular area occupied by black silver methenamine-stained matrix or stained by antibodies to type IV collagen, or the proportion occupied by cells expressing ␣-SMA, Mac-2, or CD3 were quantified as previously described. 10, 15, 16 In Masson's trichrome-stained kidney tissue, ICs are stained brown-pink and can be differentiated from cells and extracellular matrix. Accumulations of stained ICs in glomeruli were morphometrically quantified as the proportion of IC-stained area in glomerular tuft area in TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice. In interstitial areas of kidney, the numbers of Mac-2 or CD3 positive cells were counted on 15 high power fields. Liver and lung tissue sections stained with H&E were assessed for evidence of systemic injury. As previously described, the liver and lung inflammation was scored semiquantitatively on a scale of 0 to 3: 0, no inflammation; 1, mild; 2, moderate; 3, severe, with regard to the extent and density of leukocytic infiltration. 15, 17 All data are expressed as mean Ϯ SEM. Statistical analysis of the data for multiple groups was performed by TSLPtg mice developed typical features of cryoglobulin-associated MPGN as described previously. 8, 10 Mice showed progressive kidney injury from age 30 days to age 50 days, with extensive mesangial cell proliferation and mesangial matrix expansion as demonstrated by glomerular hypercellularity and increase in silver methanamine-stained extracellular matrix (Figure 1 , A-P and Table 1 ). Mesangial cell activation, as assessed by ␣-SMA expression, was also markedly increased. FcR␥ Ϫ/Ϫ mice have no renal pathology, comparable with wild-type mice. In contrast, TSLPtg/FcR␥ Ϫ/Ϫ mice developed kidney disease comparable with TSLPtg mice, with glomerular hypercellularity, mesangial matrix expansion (% silver-stained extracellular matrix area/glomerular tuft area (age 30 3 50 days): TSLPtg, 9.8 Ϯ 0.9 314.5 Ϯ 1. Functionally, TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice had similar levels of proteinuria as assessed by urine albumin/ creatinine (ug/mg) ratio (age 30 
Leukocyte Infiltration and Fc␥RI and Fc␥RIII Receptor Expression in Kidneys in TSLPtg and TSLPtg/FcR␥
Ϫ/Ϫ Mice Macrophage and T cell infiltration in glomeruli and interstitium were assessed immunohistochemically by Mac-2 expression and CD3 expression, respectively (Figure 2 , A-H and Table 1 ). Both TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice had a marked macrophage influx in glomeruli. There were fewer glomerular macrophages in TSLPtg/ FcR␥ Ϫ/Ϫ mice compared with TSLPtg mice, but the difference was not statistically significant. There was no difference for T cell infiltration in glomeruli between the two groups. In interstitium, both groups had similarly increased numbers of macrophages and T cells compared with wild-type and FcR␥ Ϫ/Ϫ mice. As quantified by ELISA, serum immunoglobulins including IgG1, IgG2a, IgG2b, IgG3, and IgM were dramatically increased in both TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice ( Table 2) . Levels of IgG1 and IgG3 were similar between the two groups. TSLPtg/FcR␥ Ϫ/Ϫ mice had a trend toward higher IgG2a, IgG2b, and IgM levels though these differences between TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice were not statistically significant. FcR␥ Ϫ/Ϫ and wildtype mice had comparable serum immunoglobulins levels (Table 2) .
TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ Mice Had Similar Systemic Lesions
TSLPtg/FcR␥ Ϫ/Ϫ mice demonstrated cryoglobulinemiaassociated systemic lesions identical to TSLPtg mice as described previously. 8 They had massive splenic enlargement and had significantly increased weights of lungs, with a trend toward increased liver weights, as compared with wild-type and FcR␥ Ϫ/Ϫ mice ( Figure 7 ). The liver showed extensive portal inflammation with extension to hepatic parenchyma. The lung showed perivascular and peribronchiolar inflammation (Figure 8 , A-H), with inflammatory infiltrates composed of both lymphoid cells and monocytes/macrophages labeled immunohistochemically by the Mac-2 antibody (data not shown). Semiquantitative assessment showed similar degrees of lung and liver inflammation in TSLPtg and TSLPtg/FcR␥ Ϫ/Ϫ mice (Table 3) .
Discussion
There is a widely accepted paradigm that the two classes of Fc␥Rs exist in mice-one class of activating Fc␥RI, III and the recently identified Fc␥RIV, which have a common FcR␥ chain, and one class consisting of the inhibitory Fc␥RIIb. 4, 7 The paradigm holds that the balance of their activities determines the extent of local inflammatory responses to tissue injuries initiated by deposition of immune complexes. Binding of the activating Fc␥Rs leads to activation of signaling molecules and subsequent activation of phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators. 4, 6 Activating Fc␥Rs are important for the amplification of immune complex-mediated diseases. FcR␥ deficiency protects NZB/NZW F1 mice from developing pathological features of lupus glomerulonephritis even though IC deposition in glomeruli is unaffected. 11 FcR␥ Ϫ/Ϫ mice are also protected from nephrotoxic nephritis. 18 In contrast, the inhibitory receptor Fc␥RIIb has been found to be an important negative regulator of immune responses and B cell activation. 5 The previous demonstration that Fc␥RIIb deficiency aggravates kidney disease in TSLPtg mice indicates the important inhibitory role of Fc␥RIIb in this model of glomerulonephritis and the overall paradigm that inflammation is regulated by balanced Fc receptor engagement.
However, there is evidence that the applicability of this paradigm is not universal. It is somewhat paradoxical that although the FcR␥-deficient mice were protected from nephrotoxic nephritis, Fc␥RIII knockout and Fc␥RI and III double knockout mice developed similar nephritis as wild-type mice. 18 Another study of nephrotoxic nephritis showed both FcR␥ Ϫ/Ϫ and Fc␥RI/III double knockout mice were protected, while Fc␥RIII knockout mice were only partially protected from the disease. 19 In sharp contrast to the studies in the lupus model of NZB/NZW F1 mice, FcR␥ deficiency afforded no protection from development of lupus glomerulonephritis in the MRL/lpr mouse model of lupus. 20 The present study provides new evidence that the sum of activities of the activating Fc␥Rs may result in little or no significant effects of these receptors in mediating progression of glomerulonephritis in some settings, such as cryoglobulinemic glomerulonephritis, and indeed, as discussed below, may even act to inhibit the initiating event of IC deposition in this setting.
Leukocyte accumulation, including monocyte/macrophage influx after deposition of ICs is an important feature of glomerulonephritis, especially in MPGN. Macrophages express all four Fc␥Rs. 21, 22 Fc␥R-mediated endocytosis and phagocytosis by macrophages is important for clearance of IgG containing ICs, including soluble ICs and cells coated by IgG. 21, 23 Macrophages from FcR␥ deficient mice cannot phagocytose ICs, analogous to ligation of Fc␥RIIb, which inhibits phagocytosis. 22, 24 In TSLPtg mice, ICs containing cryoglobulins are deposited extensively in glomeruli. Lack of activating Fc␥Rs in TSLPtg/FcR␥ Ϫ/Ϫ mice results in greater accumulation of IC deposits in glomeruli. Clearance of circulating ICs also relies on phagocytic cells, mainly macrophages, in the spleen and the liver. Deficiency of activating Fc␥Rs on macrophages in these organs presumably results in diminished phagocytosis by these cells, leading to the increased IC deposits in the kidney and increased circulating cryoglobulins observed in TSLPtg/FcR␥ Ϫ/Ϫ mice. This study builds on a body of evidence that indicates Fc receptors on infiltrating monocyte/macrophages are principle determinants of amplification and progression of glomerulonephritis. There is some evidence that cultured human mesangial cells normally do not express Fc␥Rs, but can express Fc␥RI and Fc␥RIII after IFN-␥ stimulation in vitro. 25, 26 One study identified low constitutive expression of Fc␥RIIb, but not Fc␥RI and Fc␥RIII in normal glomeruli of C57BL/6 mouse. 27 In anti-GBM nephritis of the mice it was found that glomerular expression of Fc␥RIII mRNA was induced. But whether this glomerular Fc␥RIII resulted from either infiltrating Fc␥RIII-positive cells and/or induction of Fc␥RIII expression on normally Fc␥RIII-negative resident kidney cells was not established. 27 We used double immunostaining of kidney tissue for Fc␥RI and Fc␥RIII with the macrophage markers CD68 or Mac-2, and the activated mesangial cell marker ␣-SMA, to demonstrate that most of the Fc␥RI- 28 and that FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. 29 We cannot exclude the possibility that ␣-SMA-negative mesangial cells may express Fc␥RI and Fc␥RIII, for ␣-SMA expression is generally limited to only the activated mesangial cells in the mouse.
In the glomeruli of TSLPtg mice, there are also significant IgM and IgA deposits. Much less is known about Fc receptors for IgM and IgA. Fc␣RI (CD89), which binds IgA, has been identified in human, but not in mouse. 30 A human FcR has been identified on B cells but not on macrophages. An Fc receptor for both IgA and IgM, named Fc␣/R, has been identified in both human and mouse tissues. Fc␣/R was found to be expressed by B cells and macrophages and also by kidney tubular epithelial cells, but was not expressed by glomerular cells. 31 A specific role for IgM, IgA, and Fc receptors that specifically bind to these Ig classes therefore remains uncertain in the development of kidney lesion in IC-mediated glomerulonephritis.
Besides acting on Fc receptors on effector cells, immune complexes can also activate complement pathways to induce injury. However, in TSLPtg mice, C1q staining is absent and C3 deposition is much less than IgG and IgM deposition. Our previous studies showed that overexpression of complement receptor-1 related protein Y, which blocks the classic and alternative pathways of complement activation through inhibition of C3 convertase, did not protect the kidney injury in TSLPtg mice. 32 Our studies also showed factor B deficiency with inhibition of the alternate pathway of complement activation, either alone or in addition to complement receptor-1 related protein Y overexpression, did not alleviate, but instead aggravated the renal lesion in TSLPtg mice. 33, 34 These results demonstrate complement activation may not play a substantially detrimental role in this IC-mediated inflammation, consistent with some other animal studies. 12 A critical question remains as to the key determinants of leukocyte recruitment in cryoglobulinemic MPGN if they are not dependent on complement or activating Fc␥Rs. We have shown previously, in contrast to the current findings with activating Fc␥Rs, that the inhibitory receptor Fc␥RIIb is a critical mediator of glomerulonephritis and the recruitment of leukocytes. 10 We have not yet tested the role of specific chemokines in recruitment of leukocytes to sites of glomerular injury in this model, but believe they are important mediators of this process.
Relevant to our findings is a recent study by Hida et al, 35 showing FcR␥ chain constitutively associates with the transmembrane domain of the ␤ chain of the interleukin-3 receptor, thereby mediating interleukin-3 signal transduction, which in turn regulates production of interleukin-4 in basophils. It was not determined in their study to what extent this finding might be generalized to other classes of leukocytes, but a generalized scenario could have broad consequences for regulation of immune injury. For example, FcR␥ deficiency would then be expected to impair the ability of the host to mount a Th2 type immune response, based on impaired production of interleukin-4. Testing of this possibility will be important in future studies of glomerulonephritis.
In conclusion, we demonstrated deficiency of activating Fc␥Rs does not confer protection in the TSLPtg model of immune complex-mediated MPGN. TSLPtg mice deficient in activating Fc␥Rs develop kidney disease comparable with that of TSLPtg mice and in some ways show exacerbation of disease parameters with higher levels of circulating cryoglobulins and more immune complex deposition in glomeruli. This study provides suggestive evidence that activating Fc␥Rs may be important for the clearance of immune complexes both from the circulation and from deposits in tissues. Substantiation of this suggestive evidence may be achieved by generation of chimeric TSLPtg/FcR␥ Ϫ/Ϫ mice by transplantation of bone marrow from FcR␥ ϩ/ϩ mice. These chimeric mice would allow more definitive testing of the importance of FcR␥ ϩ/ϩ monocytes/macrophages for removal of circulating and deposited immune complexes. Given the evidence that activating Fc␥Rs may also have protective effects in diseases associated with immune complex deposition, caution should be taken when considering new therapeutic strategies that target activating Fc␥Rs for diseases such as immune complex-mediated glomerulonephritis.
